Sino Biopharmaceutical Unveils Respiratory Drug Breakthroughs

Sino Biopharmaceutical (HK:1177) has released an update.

Sino Biopharmaceutical Limited has announced that it will present research findings on two of their innovative drugs at the 2024 European Respiratory Society meeting. The drugs, TQC3721, a treatment for COPD, and TQC2731, a therapy for asthma and chronic sinusitis, represent significant advancements in the respiratory disease treatment field. This milestone underscores the company’s rapid progress and ongoing commitment to developing new and effective pharmaceuticals.

For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.